-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $95

Benzinga·07/10/2026 11:24:25
Listen to the news
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $110 to $95.